952518-97-7 Usage
Description
4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine is a heterocyclic compound that features a pyrazol group attached to a pyrrolo[2,3-d]pyrimidine core. This unique molecular structure endows it with potential applications in medicinal chemistry, particularly as a building block for the development of therapeutic agents.
Uses
Used in Pharmaceutical Industry:
4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine is used as a key intermediate in the synthesis of deazapurine derivatives, which are a class of compounds with significant biological activity. One notable example is Ruxolitinib (R702000), a potent and selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor. 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine has been approved for the treatment of myeloproliferative neoplasms and psoriasis, demonstrating its effectiveness in managing these conditions by targeting the JAK/STAT signaling pathway, which plays a crucial role in immune response and cell growth regulation.
Check Digit Verification of cas no
The CAS Registry Mumber 952518-97-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,5,1 and 8 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 952518-97:
(8*9)+(7*5)+(6*2)+(5*5)+(4*1)+(3*8)+(2*9)+(1*7)=197
197 % 10 = 7
So 952518-97-7 is a valid CAS Registry Number.
952518-97-7Relevant articles and documents
Preparation of 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine
-
Paragraph 0023; 0028-0029, (2021/11/03)
The invention relates to a preparation method of 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin. Specifically, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidine acetonitrile is subjected to a chemical reaction under the action of acid, so the preparation of the 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine is realized.
Preparation method of key intermediate 2 for synthesizing baricitinib
-
Paragraph 0084; 0085; 0100; 0111; 0112, (2018/04/28)
The invention relates to a preparation method of a key intermediate 2 for synthesizing baricitinib. The preparation method comprises the following process steps: respectively synthesizing an intermediate A, an intermediate B, an intermediate D and the key intermediate 2. The preparation method has the advantages that commercially available raw materials, i.e. 1H-pyrazole-4-formic acid (SM1), ethylcyanoacetate (SM2), 2-bromo-1,1-diethoxyethane (SM3) and formamidine acetate ( SM4) are used as starting materials, and the key intermediate 2 is obtained after only four steps of chemical reactionsare carried out; the use of starting materials such as 4-chloropyrrolo[2,3-d]pyrimidine and pyrazol borate which are high in material cost is avoided, and the production cost of the key intermediate 2is lowered.
